Answers are grounded in this paper and cite their sources.
Systemic mastocytosis (SM), first reported in 1949 1 and defined by the World Health Organization (WHO) classification, 2 can be challenging to diagnose.4][5][6][7][8] Testing methodology has been improved over time, but challenges remain.We present 15 cases in which resolution of discrepant laboratory results was needed to establish a diagnosis.We retrospectively identified patients from a MC registry 9 who underwent evaluation for SM using 2017 WHO criteria 2 and tryptase genotyping for hereditary-α tryptasemia (HαT) 10 and met at least 1 of following 4 criteria: (1) ≥2 methods of KIT p.D816V testing had discordant results, (2) basal serum tryptase (BST) values were variably >20 ng/mL, (3) there were discordant results of MC CD25 expression assessed using FC and IHC or among clinical laboratories for IHC alone, or (4) there were <25% spindled MCs or <2 MC aggregates in patients meeting other diagnostic criteria.
No takes yet. Share an insight, caveat, or question.
Boggs et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: